Summary & Overview
HCPCS Level II J7210: Injection, Factor VIII (Afstyla), 1 I.U.
HCPCS Level II code J7210 identifies recombinant factor VIII (Afstyla) dosed per 1 international unit, used for treatment and prevention of bleeding in people with hemophilia A. This biologic injectable is clinically important for managing bleeding risk and maintaining hemostasis, and it represents a meaningful cost component in specialty pharmacy and outpatient infusion care.
Key national payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the code’s clinical purpose, typical sites of service, and the payer landscape addressed in the publication. The analysis covers reimbursement benchmarks, utilization patterns, coding and billing considerations tied to administration in outpatient infusion and office settings, and relevant policy updates affecting coverage and prior authorization practices.
The publication provides practical reference material for billing staff, revenue cycle teams, and clinicians involved in hemophilia care: a clear description of the service line, common billing modifiers and claims considerations (listed separately), and where to look for related coding guidance. Data elements not provided in the input are identified as unavailable.
Billing Code Overview
HCPCS Level II code J7210 represents an injection of factor VIII (antihemophilic factor, recombinant) — product Afstyla, billed per 1 international unit (I.U.). This code describes a recombinant clotting factor used for treatment and prevention of bleeding in patients with hemophilia A.
-
Service type: Injectable biologic therapy for coagulation factor replacement
-
Typical site of service: Hospital outpatient departments, physician offices, infusion centers, and other outpatient infusion settings
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult or pediatric individual with congenital hemophilia A presenting for scheduled outpatient factor replacement therapy using recombinant antihemophilic factor (Afstyla). The clinical workflow commonly occurs in an infusion center, hospital outpatient infusion suite, or home health setting with a trained nurse. The visit includes verification of patient identity and weight, review of current factor activity and inhibitor status, calculation of required international units (I.U.) based on weight and target trough levels, preparation and reconstitution of J7210 vials, verification of lot number and expiration, and documentation of dose administered. For patients with active bleeding or perioperative management, dosing is higher and coordinated with the surgical team. Common documentation elements include diagnosis, dose in I.U., lot and expiration, route (intravenous), site of infusion, start and stop times, any pre-medications, and patient response. Billing uses the HCPCS Level II code J7210 reported per 1 I.U. with appropriate modifiers for place of service, provider involvement, or special circumstances, and linkage to hemophilia-related ICD-10 diagnoses for medical necessity and coverage determination.
Coding Specifications
| Modifier | Description | When to Use |
|---|